Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer

Author(s): Vlachogianni T | Fiotakis K | Loridas S | Perdicaris S | Valavanidis A
Volume: 2013
Issue: default
Year: 2013

Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter

Author(s): Goldfinger LE | Lee S
Volume: 2013
Issue: default
Year: 2013

Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer

Author(s): Karam SD | Horne ZD | Hong RL | Baig N | Gagnon GJ | McRae D | Duhamel D | Nasr NM
Volume: 2013
Issue: default
Year: 2013

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond

Author(s): Suda K | Mitsudomi T
Volume: 2013
Issue: default
Year: 2013

Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases

Author(s): Herder GJM | Codrington H | Colder CD | Aerts JG
Volume: 2013
Issue: default
Year: 2013

EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?

Author(s): Wang QS | Mou JH | Yang X | He Y | Li ZP | Luo QY | Li YQ | Lin L | Ma Y | Xiao HL
Volume: 2013
Issue: default
Year: 2013

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Author(s): Sugiura Y | Nemoto E | Kawai O | Ohkubo Y | Fusegawa H | Kaseda S
Volume: 2013
Issue: default
Year: 2013

MET overexpression and gene amplification in NSCLC: a clinical perspective

Author(s): Landi L | Minuti G | D'Incecco A | Salvini J | Cappuzzo F
Volume: 2013
Issue: default
Year: 2013

Targeted inhibition in tumors with ALK dependency

Author(s): Kwak EL | Clark JW | Shaw AT
Volume: 2013
Issue: default
Year: 2013

Association of p21 Ser31Arg and p53 Arg72Pro polymorphisms with lung cancer risk in CAPUA study

Author(s): Souto-García A | Fernández-Somoano A | Pascual T | Álvarez-Avellón SM | Tardón A
Volume: 2012
Issue: default
Year: 2012

Update on biomarkers for the detection of lung cancer

Author(s): Jantus-Lewintre E | Usó M | Sanmartín E | Camps C
Volume: 2012
Issue: default
Year: 2012

MET targeted therapy for lung cancer: clinical development and future directions

Author(s): Feng Y | Ma PC
Volume: 2012
Issue: default
Year: 2012

Non-small cell lung cancer: the era of targeted therapy

Author(s): Antonoff MB | D'Cunha J
Volume: 2012
Issue: default
Year: 2012

Lung cancer in women

Author(s): Barrera-Rodriguez R | Morales-Fuentes J
Volume: 2012
Issue: default
Year: 2012

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

Author(s): Zienolddiny S | Skaug V
Volume: 2012
Issue: default
Year: 2011

A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer

Author(s): Yokoi T | Tamaki T | Shimizu T | Nomura S
Volume: 2012
Issue: default
Year: 2012

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer

Author(s): Berghmans T | Remmelink M | Awada A
Volume: 2012
Issue: default
Year: 2012

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Author(s): Takeda M | Okamoto I | Nishimura Y | Nakagawa K
Volume: 2011
Issue: default
Year: 2011

Afatinib treatment in advanced non-small cell lung cancer

Author(s): Hurwitz JL | Scullin P | Campbell L
Volume: 2011
Issue: default
Year: 2011

Effectiveness of maintenance treatments for nonsmall cell lung cancer

Author(s): Eadens MJ | Robinson SI | Price KA
Volume: 2011
Issue: default
Year: 2011

Emerging treatment options in the management of non-small cell lung cancer

Author(s): Filosso PL | Sandri A | Oliaro A | Filippi AR | Cassinis MC | Ricardi U | Lausi P | Asioli S | Ruffini E
Volume: 2011
Issue: default
Year: 2011